326 related articles for article (PubMed ID: 32452919)
1. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
Courbon G; Martinez-Calle M; David V
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
[TBL] [Abstract][Full Text] [Related]
2. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
3. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.
Czaya B; Faul C
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461904
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23 is pumping iron: C-terminal-fibroblast growth factor 23 cleaved peptide and its function in iron metabolism.
Courbon G; David V
Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):368-374. PubMed ID: 38661434
[TBL] [Abstract][Full Text] [Related]
5. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.
Wolf M; White KE
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):411-9. PubMed ID: 24867675
[TBL] [Abstract][Full Text] [Related]
6. New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis.
Mace ML; Olgaard K; Lewin E
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233840
[TBL] [Abstract][Full Text] [Related]
7. Ironing out the cross talk between FGF23 and inflammation.
David V; Francis C; Babitt JL
Am J Physiol Renal Physiol; 2017 Jan; 312(1):F1-F8. PubMed ID: 27582104
[TBL] [Abstract][Full Text] [Related]
8. Update on fibroblast growth factor 23 in chronic kidney disease.
Wolf M
Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
[TBL] [Abstract][Full Text] [Related]
9. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
[TBL] [Abstract][Full Text] [Related]
10. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
[TBL] [Abstract][Full Text] [Related]
11. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
[TBL] [Abstract][Full Text] [Related]
12. Inflammation regulates fibroblast growth factor 23 production.
Francis C; David V
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):325-32. PubMed ID: 27191351
[TBL] [Abstract][Full Text] [Related]
13. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
Edmonston D; Wolf M
Nat Rev Nephrol; 2020 Jan; 16(1):7-19. PubMed ID: 31519999
[TBL] [Abstract][Full Text] [Related]
14. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
15. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
[TBL] [Abstract][Full Text] [Related]
16. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis.
Takkavatakarn K; Wuttiputhanun T; Phannajit J; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Int Urol Nephrol; 2022 Feb; 54(2):309-321. PubMed ID: 33797709
[TBL] [Abstract][Full Text] [Related]
18. FGF23 production by osteocytes.
Bonewald LF; Wacker MJ
Pediatr Nephrol; 2013 Apr; 28(4):563-8. PubMed ID: 22983423
[TBL] [Abstract][Full Text] [Related]
19. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
20. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
